Sensex Rises Over 245 Points; Divi’s Lab Surges 7% As USFDA Lifts Import Alert

After opening the day on a positive note, the share markets in India continued to witness buying interest tracking global markets. Barring FMCG stocks, all sectoral indices are trading in green, with stocks in the information technology sector & PSU sector leading the gains.

The BSE Sensex is trading higher by 245 points (up 0.8%) while the NSE Nifty is trading higher by 57 points (up 0.6%). The BSE Mid Cap index and BSE Small Cap index both are trading up by 0.4%. Gold prices, per 10 grams, are trading at Rs 27,629 levels. Silver price, per kilogram is trading at Rs 35,563 levels. Crude oil is trading at Rs 2,864 per barrel. The rupee is trading at 64.73 to the US$.

Due to technical reasons in the cash market, trading was stopped in cash and F&O (futures and options) segment of the NSE.

However, at 12:30 pm, trade finally resumed after being shut for almost the entire morning session though multiple dealers were still facing issues in the cash market.

Pharma stocks are trading on a mixed note with Divi’s Laboratories and Dishman Pharma leading the gains. As per an article in a leading financial daily, Zydus Cadila has received approval from the US health regulator to market Doxazosin tablets.

The tablets are used for treatment of high blood pressure and urinary retention associated with enlargement of the prostate gland.

The company has received the final approval from the United States Food and Drug Administration (USFDA) to market Doxazosin tablets USP, 1 mg, 2 mg, 4 mg, and 8 mg.

Meanwhile, the company has also received the tentative approval from the USFDA to market Lurasidone Hydrochloride Tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg. The drug is used in the treatment of schizophrenia.

Reportedly, both Doxazosin tablets and Lurasidone Hydrochloride tablets will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.